Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection

A Brufsky, JLG Marti, A Nasrazadani… - Journal of translational …, 2020 - Springer
Amino-bisphosphonates such as zoledronic acid (ZA) can possibly ameliorate or prevent
severe COVID-19 disease by at least three distinct mechanisms:(1) as immunostimulants …

[HTML][HTML] Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine …

S Ravichandran, N Manickam, M Kandasamy - Medicine in Drug Discovery, 2022 - Elsevier
The emergence of new SARS-CoV-2 variants continues to pose an enormous public health
concern. The SARS-CoV-2 infection disrupted host immune response accounting for …

Race to arsenal COVID-19 therapeutics: Current alarming status and future directions

AK Dubey, A Singh, S Prakash, M Kumar… - Chemico-Biological …, 2020 - Elsevier
The on-going pandemic of COVID-19 wreaked by a viral infection of SARS-CoV-2, has
generated a catastrophic plight across the globe. Interestingly, one of the hallmarks of …

Dapsone and doxycycline could be potential treatment modalities for COVID-19

A Farouk, S Salman - Medical hypotheses, 2020 - ncbi.nlm.nih.gov
The World Health Organization has announced COVID-19 as a pandemic in March 2020.
COVID-19 is an infectious disease caused by the severe acute respiratory syndrome …

The PDE4 inhibitor tanimilast blunts proinflammatory dendritic cell activation by SARS-CoV-2 ssRNAs

HO Nguyen, T Schioppa, L Tiberio… - Frontiers in …, 2022 - frontiersin.org
Phosphodiesterase 4 (PDE4) inhibitors are immunomodulatory drugs approved to treat
diseases associated with chronic inflammatory conditions, such as COPD, psoriasis and …

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

MW McCarthy - Expert Opinion on Pharmacotherapy, 2022 - Taylor & Francis
ABSTRACT Introduction SARS-CoV-2, the virus that causes COVID-19, elicits a variety of
host responses ranging from asymptomatic or mild illness in most people, to severe disease …

Immunomodulators for curtailing COVID-19: a positive approach

SA Bhat, SA Rather, A Iqbal, HA Qureshi… - Journal of drug delivery …, 2020 - jddtonline.info
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is highly infectious,
spreading swiftly from man to man which has not been previously recognized in humans …

Modalities and mechanisms of treatment for coronavirus disease 2019

Z Zuo, T Wu, L Pan, C Zuo, Y Hu, X Luo… - Frontiers in …, 2021 - frontiersin.org
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly throughout the world. Although …

[HTML][HTML] AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate

M Delijewski, J Haneczok - Medicine in Drug Discovery, 2021 - Elsevier
Aims Over the past few years, AI has been considered as potential important area for
improving drug development and in the current urgent need to fight the global COVID-19 …

Targeting the pentose phosphate pathway for SARS-CoV-2 therapy

D Bojkova, R Costa, P Reus, M Bechtel, MC Jaboreck… - Metabolites, 2021 - mdpi.com
SARS-CoV-2 is causing the coronavirus disease 2019 (COVID-19) pandemic, for which
effective pharmacological therapies are needed. SARS-CoV-2 induces a shift of the host cell …